Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JDEV Acquisition Corp. is a blank check company, also known as a special purpose acquisition company (SPAC), incorporated in Delaware for the purpose of effecting a merger, capital stock exchange, asset acquisition, or similar business combination. While the company may pursue an initial business combination target in any industry, it intends to focus its search on the healthcare or healthcare-related industries. The management team is led by Chairman and CEO Joseph DeVivo, who brings extensive leadership experience from medical technology firms such as Butterfly Network and Teladoc Health. The company completed its initial public offering in May 2024 and is listed on the Nasdaq Capital Market. JDEV Acquisition leverages its team's deep expertise in medical devices and healthcare services to identify high-growth opportunities within the life sciences sector.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JDEV Acquisition.